Seven-Year Follow-Up Results Can Help HER2+ Breast Cancer Patients Avoid Overtreatment

The combination of trastuzumab and paclitaxel ' represents an important step forward in de-escalating therapy ' for HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news